Regulatory intelligence & pharmacovigilance updates, mapped to your role.

Immediate quarantine and destruction of all affected lots are mandated. Affected inventory must be checked, and customers must be notified if products have been resold or transferred.

Healthcare providers must implement the new administration protocol for Zanvastro, which is an injection every three months, and monitor for common side effects such as vomiting, back pain, and signs of aseptic meningitis.

Stakeholders must familiarize themselves with the new data elements for Individual Case Safety Reports (ICSRs) as per the revised EudraVigilance access policy effective immediately.

Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.

The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.

Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.

Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.

Applicants must adhere to new timelines: submit a rapporteurs' allocation request 9 months prior to the intended MAA submission date, and submit their Letter of Intent at least 2 months before the MAA submission.